Pharmaceutical Executive-04-01-2016

Limitations of the Drug Supply Chain Security Act for pharma-and three strategies to fix them.

Charting two years of collaborative progress in clinical trial data sharing.

The importance of betting on outcomes, not simply risk sharing, when implementing pharma-payer arrangements. .

Why the industry needs more women in senior management roles-and the three strategies to get there.

How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.

Altruism and self-interest are at the heart of European thinking on neglected diseases.

The courts, pharma, and policymakers push FDA to rethink communications policy.

The practice’s emerging-if improbable-cost-saving potential.

The challenges facing the ad industry and big Pharma are remarkably similar-a point driven home by four distinct themes at this year's 4A's Transformation conference illustrate.

Egypt is not just a sun-soaked paradise defined by pyramids and tombs, or-alternatively-a hotbed for political turmoil and revolution. It’s also a vibrant and growing market for pharmaceuticals, experts contend.

Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.